Medical/Pharmaceuticals
Copan Diagnostics Announces Leadership Change
CARLSBAD, Calif., Feb. 2, 2023 /PRNewswire/ -- COPAN Group announces the departure ofNorman Sharples, Chief Executive Officer of Copan Diagnostics, from the Company he co-founded withDaniele Triva in 1994 and the appointment of Fabrizio Mazzocchi as new CEO and member of Copan Diagnostics' board ...
2023-02-02 23:09
3185
Servier full year 2021/22 results confirm the transformation trajectory of the Group
* Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales * Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at CERi), and €1.182 billion for generics, up 2.0% (stable at CERi) * Important development...
2023-02-02 14:30
2034
Accelerating Energy Efficiency Adoption, Deep-tech Startup KrossLinker Develops a Cost-effective Aerogel Insulation
SINGAPORE, Feb. 2, 2023 /PRNewswire/ -- KrossLinker, an energy-efficiency-focused deep-tech advanced material startup, is designing and developing the world's most insulating nanomaterial, aerogel, that is low-cost, environmentally friendly, and scalable. Efficient and sustainable solutions fo...
2023-02-02 10:11
3262
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)
SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Invivoscribe is pleased to announce the appointment ofMasato Sasaki as General Manager of LabPMM GK, our reference laboratory inJapan. Mr. Sasaki brings a wealth of scientific experience with him as he served at Illumina K.K. (Japan) as a leader on their cl...
2023-02-02 05:00
2370
Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that it is advancing the clinical development of...
2023-02-01 15:00
3262
Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short
NEW YORK, Jan. 31, 2023 /PRNewswire/ -- The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the development of critical new health technologies to overcome the world's deadliest neglected diseases remained woefully inadequate and largely stagnant. Specific...
2023-01-31 21:30
1779
Mindray Unveils Next-generation BeneHeart Defibrillation Solutions to Raise Standards for Resuscitation
SHENZHEN, China, Jan. 31, 2023 /PRNewswire/ -- Mindray, a global leading medical device solutions provider, today announces the launch of next-generation BeneHeart series defibrillators, the BeneHeart D60 and D30. The new BeneHeart defibrillators aim to raise the standards for resuscitation with ...
2023-01-31 18:00
1906
Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed t...
2023-01-31 17:40
2568
Delivery of 170,000 Bottles of Azvudine Tablets During Spring Festival to Help Rural Areas Weather the Epidemic
HONG KONG, Jan. 31, 2023 /PRNewswire/ -- In response to the infection peak season of COVID-19 in rural areas that may be brought about by people returning home during Chinese New Year, Fosun Foundation announced on9 January 2023 the cooperation with Fosun Pharma and Genuine Biotech to donateRMB10...
2023-01-31 16:10
3157
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region
* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a double-digit royalties on Net Sales * CS Pharmaceuticals will receive exclusive rights for development and commercialization of Bersiporocin for the treatment of IPF and other respiratory indica...
2023-01-31 14:43
3198
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China
HANGZHOU, China and SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of patient dosing in Phase 3 clinical tr...
2023-01-31 08:00
2122
Novotech Awarded by Frost & Sullivan for Global Biotech Clinical Trials Excellence in APAC
With a proven biotech market leadership position, Novotech's compelling value proposition drives its sustained success in delivering biotech clinical trials. SAN ANTONIO, Jan. 31, 2023 /PRNewswire/ -- Frost & Sullivan recently analyzed theAsia-Pacific contract research organization industry and, ...
2023-01-31 05:37
1985
Mindray Demonstrates Its Smart Hospital Solutions at Arab Health 2023
DUBAI, UAE, Jan. 30, 2023 /PRNewswire/ -- Mindray ("the company"), a leading global provider of medical devices and solutions, is attending one of the largest and most respected exhibitions in the medical field, the Arab Health 2023 fromJan. 30 to Feb. 2. The company has exhibited its medical sol...
2023-01-30 23:30
2164
Syntach AB announces €17.5M in Blended Funding, Names Patrick NJ Schnegelsberg as New CEO, and Appoints Cansel Isikli as VP of RA/Q
LUND, Sweden, Jan. 30, 2023 /PRNewswire/ - Swedish medtech startup Syntach AB has been awarded up to €15 million in equity financing by European Innovation Council (EIC) for the development of the Syntach Cardiac Support System, a breakthrough device for patients with heart failure. This approval...
2023-01-30 21:29
2411
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
* ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. * ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. * ORSERDU is the first endocrine innovation in more than 20 years, specif...
2023-01-30 20:39
2260
Duoning Headquarters in Fengxian Biotechnology Park with Centers for R&D and Technology Applications
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Shanghai Duoning Biotechnology Co., Ltd. ("Duoning") announced that the company signed an Agreement on theTransfer of the Right to Use State-owned Construction Land with the Bureau of Planning and Natural Resources of Fengxian District,Shanghai and official...
2023-01-30 18:00
2395
MGI Makes its Mark in Dubai with Latest Platforms at MEDLAB Middle East and Arab Health
DUBAI, UAE, Jan. 30, 2023 /PRNewswire/ -- MGI Tech Co., Ltd.
2023-01-30 16:00
1983
Kalbe Consumer Health Crowned Winner at the Asia Pacific Enterprise Awards 2022 Regional Edition
SINGAPORE, Jan. 27, 2023 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite theC...
2023-01-30 11:26
2459
Chula Medicine Reveals Detection of Latent Dementia
Thai Red Cross Emerging Infectious Diseases Health Science Center, Faculty of Medicine,Chulalongkorn University has researched a blood test for markers of Alzheimer's that can give a 10-year warning, so people can be prepared to slow down the development of dementia in old age. BANGKOK, Jan. 30,...
2023-01-30 11:01
3435
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor Pimicotinib（ABSK021）has been granted the breakthrough therapy designation from FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients...
2023-01-30 11:00
2931
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
9065
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
7332
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
6976
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
6749
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
6707
